Sandra Thiemann

513 total citations
16 papers, 430 citations indexed

About

Sandra Thiemann is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Sandra Thiemann has authored 16 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in Sandra Thiemann's work include Diabetes Treatment and Management (14 papers), Diabetes Management and Research (9 papers) and Metabolism, Diabetes, and Cancer (7 papers). Sandra Thiemann is often cited by papers focused on Diabetes Treatment and Management (14 papers), Diabetes Management and Research (9 papers) and Metabolism, Diabetes, and Cancer (7 papers). Sandra Thiemann collaborates with scholars based in Germany, United States and United Kingdom. Sandra Thiemann's co-authors include Maximilian von Eynatten, Sanjay Patel, Hannele Yki‐Järvinen, S. Durán‐García, Sabine Pinnetti, Hans‐Juergen Woerle, Sudipta Bhattacharya, Julio Rosenstock, H.J. Woerle and S. Patel and has published in prestigious journals such as Journal of the American College of Cardiology, Diabetes Care and Analytical Biochemistry.

In The Last Decade

Sandra Thiemann

16 papers receiving 418 citations

Peers

Sandra Thiemann
Jennifer Newman United States
Aditya Goud United States
Liang‐Liang Ding China
Sudipta Bhattacharya United States
Harindra Rajasekeran Canada
Elizabeth Bandeira-Echtler Germany
Leili Gao China
Ike Ogbaa United States
Plamen Kozlovski United States
Surya Panicker Rajeev United Kingdom
Jennifer Newman United States
Sandra Thiemann
Citations per year, relative to Sandra Thiemann Sandra Thiemann (= 1×) peers Jennifer Newman

Countries citing papers authored by Sandra Thiemann

Since Specialization
Citations

This map shows the geographic impact of Sandra Thiemann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Thiemann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Thiemann more than expected).

Fields of papers citing papers by Sandra Thiemann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Thiemann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Thiemann. The network helps show where Sandra Thiemann may publish in the future.

Co-authorship network of co-authors of Sandra Thiemann

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Thiemann. A scholar is included among the top collaborators of Sandra Thiemann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Thiemann. Sandra Thiemann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
McBride, Helen J., Ashley Frazer‐Abel, Sandra Thiemann, et al.. (2023). Functional similarity of ABP 959 and eculizumab in simulated serum models of aHUS and NMOSD. Annals of Hematology. 102(12). 3299–3309. 4 indexed citations
2.
Thiemann, Sandra, et al.. (2022). Utility of SPR technology in biotherapeutic development: Qualification for intended use. Analytical Biochemistry. 654. 114804–114804. 8 indexed citations
3.
4.
Groop, Per‐Henrik, Mark E. Cooper, Vlado Perkovic, et al.. (2017). Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA ‐ T2D trial. Diabetes Obesity and Metabolism. 19(11). 1610–1619. 114 indexed citations
5.
Lehrke, Michael, Lawrence A. Leiter, Uwe Hehnke, et al.. (2016). Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials. Journal of Diabetes and its Complications. 30(7). 1378–1384. 7 indexed citations
6.
Thiemann, Sandra, et al.. (2016). Linagliptin reduces the diabetic nephropathy score, DN_Score, in patients with T2DM and microalbuminuria: A predefined substudy from the MARLINA-T2D™ trial. Diabetes Research and Clinical Practice. 120. S129–S129. 1 indexed citations
7.
Ross, Stuart A., A. Enrique Caballero, Stefano Del Prato, et al.. (2016). Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. Postgraduate Medicine. 128(8). 747–754. 5 indexed citations
8.
9.
Gallwitz, Baptist, et al.. (2015). Kardiovaskuläre Studien-Endpunkte bei Typ-2-Diabetes und die Sulfonylharnstoff-Kontroverse. DMW - Deutsche Medizinische Wochenschrift. 140(11). 831–834. 3 indexed citations
10.
Jax, Thomas, Maximilian von Eynatten, Alin Stirban, et al.. (2015). A RANDOMIZED, ACTIVE- AND PLACEBO-CONTROLLED, THREE-PERIOD CROSSOVER TRIAL TO INVESTIGATE SHORT-TERM EFFECTS OF THE DIPEPTIDYL PEPTIDASE-4 INHIBITOR LINAGLIPTIN ON ENDOTHELIAL FUNCTION IN TYPE 2 DIABETES. Journal of the American College of Cardiology. 65(10). A2080–A2080. 6 indexed citations
11.
Durán‐García, S., Hannele Yki‐Järvinen, Julio Rosenstock, et al.. (2015). Efficacy and safety of linagliptin as add‐on therapy to basal insulin and metformin in people with Type 2 diabetes. Diabetic Medicine. 33(7). 926–933. 6 indexed citations
12.
13.
Yki‐Järvinen, Hannele, Julio Rosenstock, S. Durán‐García, et al.. (2013). Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes. Diabetes Care. 36(12). 3875–3881. 117 indexed citations
14.
Araki, Eiichi, Ryuzo Kawamori, Nobuya Inagaki, et al.. (2012). Long‐term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Obesity and Metabolism. 15(4). 364–371. 26 indexed citations
15.
16.
Yki‐Järvinen, Hannele, S. Durán‐García, Sabine Pinnetti, et al.. (2012). Efficacy and Safety of Linagliptin as Add-on Therapy to Basal Insulin in Patients With Type 2 Diabetes. Canadian Journal of Diabetes. 36(5). S39–S39. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer Newman Breakdown of academic impact, for papers by Aditya Goud Breakdown of academic impact, for papers by Liang‐Liang Ding Breakdown of academic impact, for papers by Sudipta Bhattacharya Breakdown of academic impact, for papers by Harindra Rajasekeran Breakdown of academic impact, for papers by Elizabeth Bandeira-Echtler Breakdown of academic impact, for papers by Leili Gao Breakdown of academic impact, for papers by Ike Ogbaa Breakdown of academic impact, for papers by Plamen Kozlovski Breakdown of academic impact, for papers by Surya Panicker Rajeev
Rankless by CCL
2026